Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
24 January 2023 - 11:22PM
Edgar (US Regulatory)
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2023
Commission File Number: 001-39137
AnPac Bio-Medical Science Co., Ltd.
801 Bixing Street, Bihu County
Lishui, Zhejiang Province 323006
The People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
Entry Into Definitive Investment Agreements
In December 2022 and January 2023, AnPac Bio-Medical Science Co., Ltd.
(the “Company”) signed definitive investment agreements with several third party investors, where the investors agreed to
purchase 29,714,279 newly issued Class A ordinary shares (1,485,714 American Depositary Shares or “ADSs”) of the Company at
a price of US$0.175 per ordinary share or US$3.5 per ADS (1:20 ADS-to-share ratio), for a total purchase price of $5.2 million. Concurrently,
for each Class A ordinary share purchased, the investors will receive from the Company two warrants with each warrant to purchase one
Class A ordinary share at an exercise price of $0.21 per ordinary share (2,971,428
ADS an at exercise price of $4.20 per ADS). The warrants are exercisable within 2 years from the date of issuance. The closing is expected
to take place within 30 days after signing.
This Report on Form 6-K shall not constitute an offer to
sell or the solicitation of an offer to buy any securities of the Company.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| |
AnPac Bio-Medical Science Co., Ltd. |
| |
|
| |
|
By: |
/s/Haohan Xu |
| |
|
Name: |
Haohan Xu |
| |
|
Title: |
Co-Chief Executive Officer |
Dated: January 24, 2023
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Mar 2024 to Apr 2024
AnPac Bio Medical Science (NASDAQ:ANPC)
Historical Stock Chart
From Apr 2023 to Apr 2024
